Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Depreciation & Amortization (CF): 2014-2024

Historic Depreciation & Amortization (CF) for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Dec 2024 value amounting to $8.0 million.

  • Syndax Pharmaceuticals' Depreciation & Amortization (CF) fell 21.38% to -$176,000 in Q3 2019 from the same period last year, while for Sep 2019 it was -$725,000, marking a year-over-year decrease of 466.41%. This contributed to the annual value of $8.0 million for FY2024, which is 33.33% down from last year.
  • As of FY2024, Syndax Pharmaceuticals' Depreciation & Amortization (CF) stood at $8.0 million, which was down 33.33% from $12.0 million recorded in FY2023.
  • In the past 5 years, Syndax Pharmaceuticals' Depreciation & Amortization (CF) ranged from a high of $43.0 million in FY2021 and a low of $90,000 during FY2020.
  • Over the past 3 years, Syndax Pharmaceuticals' median Depreciation & Amortization (CF) value was $12.0 million (recorded in 2023), while the average stood at $17.7 million.
  • Per our database at Business Quant, Syndax Pharmaceuticals' Depreciation & Amortization (CF) surged by 47,677.78% in 2021 and then slumped by 63.64% in 2023.
  • Over the past 5 years, Syndax Pharmaceuticals' Depreciation & Amortization (CF) (Yearly) stood at $90,000 in 2020, then soared by 47,677.78% to $43.0 million in 2021, then fell by 23.26% to $33.0 million in 2022, then plummeted by 63.64% to $12.0 million in 2023, then tumbled by 33.33% to $8.0 million in 2024.